|Bid||9.52 x 4000|
|Ask||9.70 x 3100|
|Day's Range||9.30 - 9.69|
|52 Week Range||4.81 - 13.33|
|Beta (5Y Monthly)||2.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.17|
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
All five patients in an early-stage trial given the one-time treatment, giroctocogene fitelparvovec, did not have spontaneous bleeding episodes or require infusions of the blood-clotting protein they otherwise lack, the companies said. Pfizer and Sangamo's therapy is one of several treatments being developed for hemophilia A, as an alternative to the current practice that requires regular infusions to replace the missing protein, factor VIII. On Wednesday, a rival gene therapy by BioMarin Pharmaceutical Inc was found to reduce bleeding episodes by over 90% in patients treated four years ago.
Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525, or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. All five patients with severe hemophilia A who received the 3e13 vg/kg dose showed sustained factor VIII (FVIII) activity levels, with a median of 64.2% via chromogenic assay (patient-level geometric means after week 9 post-infusion). No patients experienced bleeding events or required FVIII infusions. The factor VIII activity levels reflect measurements up to 61 weeks, the extent of follow-up for the longest-treated patient in the cohort. These data are being presented today as a late-breaking oral abstract at the World Federation of Hemophilia 2020 World Congress, which is being held virtually from June 14 to June 19, 2020.
CRISPR Therapeutics (NASDAQ: CRSP) and Sangamo Therapeutics (NASDAQ: SGMO) are clinical-stage biotech companies aiming to capture a slice of the cell and gene therapy market, which will grow to be $12 billion in size by 2025. As gene therapy companies, both have developed technology platforms that make it possible to alter the genome and therefore change the behavior of a patient's cells. Any investor would benefit from learning about these biotech companies and the exciting world of gene editing.
Shares of Sangamo Therapeutics surged Thursday ahead of an update next week for its Pfizer-partnered gene therapy in hemophilia A. SGMO stock popped in high volume.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m. ET.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Bank of America 2020 Health Care Conference on Thursday, May 14 at 4:20 p.m. ET.
With me this afternoon on this call are several members of the Sangamo senior management team, including Sandy Macrae, Chief Executive Officer; Sung Lee, Chief Financial Officer; Stephane Boissel, Head of Corporate Strategy; Adrian Woolfson, Head of Research and Development; Mark McClung, Chief Business Officer; and Bettina Cockroft, Chief Medical Officer. Slides from our corporate presentation can be found in our website sangamo.com under the Investors and Media section in the Events and Presentations page.
Sangamo (SGMO) delivered earnings and revenue surprises of -60.87% and -57.78%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported first quarter 2020 financial results and recent business highlights.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that it is changing its 2020 Annual Meeting of Stockholders to a virtual-only format due to public health and safety concerns related to the coronavirus (COVID-19) pandemic.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2020 financial results after the market closes on Monday, May 11, 2020. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
Take Cara Therapeutics (NASDAQ: CARA) and Sangamo Therapeutics (NASDAQ: SGMO), for example. One thing that both Cara and Sangamo have in common, though, are promising pipeline candidates. Investors have placed a greater value on Sangamo's pipeline based on the company's higher market cap.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 12th to May 15th, 2020, in a virtual format.
Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrify’s proprietary induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) and Sangamo’s zinc finger protein (ZFP) gene-engineered chimeric antigen receptor regulatory T cell (CAR-Treg) technology.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of D. Mark McClung as Executive Vice President and Chief Business Officer. Mr. McClung will oversee commercial strategic planning, alliance management and corporate and business development.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the closing of its previously announced sale of stock to Biogen Inc. (Nasdaq: BIIB) and that the global licensing collaboration agreement with Biogen for the development and commercialization of gene regulation therapies for Alzheimer’s, Parkinson’s, neuromuscular and other neurological diseases is now effective. Under the terms of the collaboration, Sangamo has received $225 million from the purchase by Biogen of newly issued Sangamo stock and will receive an upfront license fee of $125 million from Biogen no later than May 8, 2020. Additionally, Sangamo is eligible to earn up to $2.37 billion in other development, regulatory and commercial milestone payments, including up to $925 million in pre-approval milestone payments and up to $1.445 billion in first commercial sale and other sales-based milestone payments. Sangamo is also eligible to earn tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration.
For his first "Executive Decision" segment of Mad Money Friday night, Jim Cramer spoke with Sandy Macrae, president and CEO of Sangamo Therapeutics Inc. , a biotech company whose shares rose 4.9% after the company announced a new partnership with Biogen . Macrae explained that the partnership with Biogen allows Sangamo to perform early-stage research on a number of genes that Biogen is interested in and Biogen will then help to develop and commercialize the drugs that come from that research. Sangamo is currently working on treatments for both Alzheimer's and Parkinson's disease.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
Sangamo Therapeutics and Biogen are teaming up to develop several gene regulation therapies, the biotech companies said, sending SGMO stock flying on Friday.